Palbociclib With Everolimus + Exemestane In BC

Clinical trial NCT02871791 · COMPLETED

Trial details

NCT number: NCT02871791
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Hormone Receptor (HR)-Positive Breast Cancer

Start date: 2016-08-24
Primary completion: 2020-12-03
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.